Annual Conference & Webinar Schedule

To learn more about NP Thyroid®, please visit the Acella Pharmaceuticals booth at the events listed below. Acella also invites you to attend our product theater sessions.

By clicking "Register" below, you will be redirected to the event host’s website, where you can complete your registration.

March

California Association of Nurse Practitioners
(CANP)

March 19-22 – Rancho Mirage, CA

Booth #: 107

Product Theater

Wednesday, March 19 at 6:30-8:00 pm PT
with Speaker Angela Golden, DNP, FNP-C, FAANP, FOMA

Title

Lessons in Hypothyroidism: A Look at the Unique Needs of our Patients

May

American Association of Clinical Endocrinology Annual Meeting (AACE)

May 15-17 – Orlando, FL

Booth #: 422

Product Theater

Thursday, May 15 at 10:15-11:00 am ET
with Speakers Thanh Hoang DO, FACP, FACE and Brittany Henderson, MD, ECNU

Title

Treating Hypothyroidism: A Clinical Spotlight on Desiccated Thyroid Extract

American Academy of Physician Associates
(AAPA)

May 17-21 – Denver, CO

Booth #: 1635

Product Theater

Monday May, 19 at 12:15-1:00 pm MT
with Speakers TBD

Title

TBD

June

Nurse Practitioner Associates for Continuing Education
(NPACE)

June 9-12 – Cape Cod, MA

American Association of Nurse Practitioners
(AANP)

June 17-22 – San Diego, CA

Booth #: 1817

Product Theater

Wednesday, June 18 at 11:45 am -1:00 pm PT
with Speakers Angela Mazza, DO and Barbara Dehn, NP

Title

TBD

July

Endocrine Society's Annual Meeting 2025
(ENDO)

July 12-15 – San Francisco, CA

Booth #: TBD

Product Theater

Saturday, July 12 at 12:30-1:30 pm PT
with Speakers Thanh Hoang DO, FACP, FACE, Elizabeth McAninch, MD, and David Robertson, MD

Title

The State of Desiccated Thyroid Extract in Hypothyroidism: Where We Are Now and Where We Need To Be

National Nurse Practitioner Symposium
(NNPS)

July 15-19 – Keystone, CO

Booth #: 315

Product Theater

Wednedsay, July 16
with Speaker Angela Golden, DNP, FNP-C, FAANP, FOMA

Title

Lessons in Hypothyroidism: A Look at the Unique Needs of our Patients

Florida Endocrine Association
(FEA)

July 25-27 – Orlando, FL

September

Clinical Association of California Endocrinologists
(CACE)

September 5-7 – Anaheim, CA

American Thyroid Association
(ATA)

September 10-14 – Scottsdale, AZ

Booth #: TBD

Product Theater

TBD
with Speaker TBD

Title

TBD

Nurse Practitioner Associates for Continuing Education
(NPACE)

September 22-25 – Phoenix, AZ

Texas Nurse Practitioners Annual Fall Conference
(TNP)

September 25-28 – Dallas, TX

Booth #: TBD

Product Theater

Thursday, September 25 at 12:00 pm CT
with Speaker TBD

Title

TBD

Michigan Assocation of Endocrinologists Annual Symposium
(MAE)

September 27-29 – Detroit, MI

October

Nurse Practitioners in Women's Health
(NPWH)

October 1-3 – Las Vegas, NV

Michigan Council of Nurse Practitioners Annual Conference
(MICNP)

October 10-12 – Detroit, MI

Booth #: TBD

Product Theater

TBD
with Speaker TBD

Title

TBD

New York Nurse Practitioners Association
(NYPA)

October – New York

New England Endocrine Alliance Annual Meeting
(NEEA)

Late Oct 2025

May Mid-Atlantic Society of Endocrinologists 2025 Annual Meeting (MASE)

Late Oct 2025 – Maryland

November

Nurse Practitioner Associates for Continuing Education
(NPACE)

November 2-5 – Orlando, FL

You Are About To Leave This Website

By clicking continue, this link will take you to a website to which Alora Pharmaceuticals’ Policies & Terms of Use do not apply.

Continue

You Are About To Leave This Website

By clicking continue, this link will take you to a website to which Alora Pharmaceuticals’ Policies & Terms of Use do not apply. Alora and its subsidiaries do not control the content or accuracy of third-party websites and assume no responsibility for their use.

Continue

Note that DTE products, including NP Thyroid®, have not been reviewed by the FDA for safety or efficacy.

IMPORTANT RISK INFORMATION, INCLUDING BOXED WARNING & INDICATIONS
Important Risk Information

Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
  • NP Thyroid® is contraindicated in patients with uncorrected adrenal insufficiency, untreated thyrotoxicosis, and hypersensitivity to any component of the product.
  • In the elderly and in patients with cardiovascular disease, NP Thyroid® should be used with greater caution than younger patients or those without cardiovascular disease.
  • Use of NP Thyroid® in patients with diabetes mellitus or adrenal cortical insufficiency may worsen the intensity of their symptoms.
  • The therapy of myxedema coma requires simultaneous administration of glucocorticoids.
  • Concomitant use of NP Thyroid® with oral anticoagulants alters the sensitivity of oral anticoagulants. Prothrombin time should be closely monitored in thyroid-treated patients on oral anticoagulants.
  • In infants, excessive doses of NP Thyroid® may produce craniosynostosis.
  • Partial loss of hair may be experienced by children in the first few months of therapy but is usually transient.
  • Adverse reactions associated with NP Thyroid® therapy are primarily those of hyperthyroidism due to therapeutic overdosage.
  • Many drugs and some laboratory tests may alter the therapeutic response to NP Thyroid®. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Administer at least 4 hours before or after drugs that are known to interfere with absorption. Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption.
  • NP Thyroid® should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated.

Indications

NP Thyroid® (thyroid tablets, USP) is a prescription medicine that is used to treat a condition called hypothyroidism from any cause, except for cases of temporary hypothyroidism, which is usually associated with an inflammation of the thyroid (thyroiditis). It is meant to replace or supplement a hormone that is usually made by your thyroid gland.

NP Thyroid® is also used in the treatment and prevention of normal functioning thyroid goiters, such as thyroid nodules, Hashimoto’s thyroiditis, multinodular goiter, and in the management of thyroid cancer.

Revised 10/2023